Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
punalimab
- Development stage
- Unknown
- Lead developer
- I-MAB
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Punalimab (formerly TJ-S2) is a humanized monoclonal antibody designed to target and neutralize interleukin-1 beta (IL-1β). Developed by I-Mab Biopharma, it is currently being evaluated in clinical trials for the treatment of acute gouty arthritis, particularly in patients who have contraindications, intolerance, or an inadequate response to conventional treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine. By blocking IL-1β, punalimab interrupts the inflammatory cycle responsible for the intense pain and swelling associated with gout flares. The drug is being developed by I-Mab's Hangzhou subsidiary and is part of a broader strategy to address unmet needs in inflammatory and autoimmune diseases.
- Other names
- punali monoclonal antibody普纳利单抗
02
Targets
IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on punalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on punalimab.